Related Experiment Video
Updated: Apr 14, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
The SNHG15/miR-451a/Caveolin-1 Axis Promotes Oxaliplatin Resistance in Gastric Cancer Cells by Regulating Fatty Acid
Yi Wang1, Zhongshi Hong2, Jintian Song3
1Department of Gastric Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Abstract:
Gastric cancer is a common malignant tumor of the digestive tract. Chemotherapy resistance severely limits the therapeutic effect of this disease. The competing endogenous RNA regulatory network is widely involved in the occurrence and development of various cancers and is also closely related to the generation of drug resistance. However, the underlying molecular mechanism remains to be further elucidated. This study investigated the molecular mechanism by which the long noncoding RNA SNHG15/miR-451a/Caveolin-1 (CAV1) axis mediates oxaliplatin resistance in gastric cancer through regulating fatty acid β-oxidation. Through analysis using The Cancer Genome Atlas database and qRT-PCR, it was found that SNHG15 was highly expressed in gastric cancer tissues, whereas miR-451a was lowly expressed. Bioinformatics prediction combined with dual luciferase and RNA immunoprecipitation experiments confirmed that SNHG15 could act as a molecular sponge for miR-451a, and CAV1 was the downstream target gene of miR-451a. Functional experiments demonstrated that the knockdown of miR-451a or overexpression of CAV1 could promote cell proliferation, inhibit apoptosis, and alleviate G0-G1-phase arrest while enhancing fatty acid β-oxidation. In vivo experiments further confirmed that the SNHG15/miR-451a/CAV1 axis affected gastric cancer oxaliplatin resistance by regulating fatty acid β-oxidation.
Implications:
This study revealed that SNHG15 inhibits miR-451a to upregulate CAV1 expression, thereby regulating fatty acid β-oxidation and influencing gastric cancer oxaliplatin resistance, providing new biomarkers and potential therapeutic targets for gastric cancer oxaliplatin resistance.
Insights
Gastric cancer's resistance to oxaliplatin is mediated by the SNHG15/miR-451a/Caveolin-1 axis regulating fatty acid oxidation. This pathway offers potential therapeutic targets for improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Gastric cancer is a prevalent digestive tract malignancy.
- Chemotherapy resistance, particularly to oxaliplatin, significantly hinders treatment efficacy.
- The ceRNA network's role in cancer development and drug resistance is recognized but not fully understood.
Purpose of the Study:
- To elucidate the molecular mechanism of oxaliplatin resistance in gastric cancer.
- To investigate the involvement of the lncRNA SNHG15/miR-451a/Caveolin-1 (CAV1) axis.
- To determine the role of fatty acid β-oxidation in this process.
Main Methods:
- Analysis of TCGA database and qRT-PCR for gene expression.
- Bioinformatics prediction, dual luciferase assays, and RIP experiments to confirm interactions.
- In vitro functional assays (cell proliferation, apoptosis, cell cycle) and in vivo experiments.
Main Results:
- SNHG15 was upregulated, and miR-451a was downregulated in gastric cancer tissues.
- SNHG15 acted as a sponge for miR-451a, with CAV1 as miR-451a's target.
- Knockdown of miR-451a or overexpression of CAV1 promoted proliferation, inhibited apoptosis, and enhanced fatty acid β-oxidation, impacting oxaliplatin resistance.
Conclusions:
- The SNHG15/miR-451a/CAV1 axis regulates fatty acid β-oxidation, contributing to gastric cancer oxaliplatin resistance.
- This axis represents a potential biomarker and therapeutic target for overcoming chemotherapy resistance in gastric cancer.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

